Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Severe SepsisSeptic Shock
Interventions
BIOLOGICAL

CaCP29

BIOLOGICAL

Placebo

Trial Locations (11)

Unknown

Study Site, Aachen

Study Site, Augsburg

Study Site, Bad Saarow

Study Site, Berlin

Study Site, Göttingen

Study Site, Greifswald

Study Site, Hamburg

Study Site, Jena

Study Site, Kiel

Study Site, Leipzig

Study Site, Oldenburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InflaRx GmbH

INDUSTRY

NCT02246595 - Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction | Biotech Hunter | Biotech Hunter